Innovation Pharmaceuticals Inc. (OTCPK: IPIX)
Health Care · Biotechnology · US
$0.00
+33.33% today · -60.0% 1Y
Innovation Pharmaceuticals Inc. (OTCPK: IPIX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $211.51K and employs 4 people.
Over the last twelve months the share price has lost 60.0%, trading between 0.00 and 0.05.
Tweenvest scores Innovation Pharmaceuticals Inc. across four factors: quality 33/100. Its strongest factor is quality.
IPIX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $211.51K
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.01
- Dividend yield
- —
- Beta (5Y)
- 153.11
- 52-week high
- $0.05
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 528.77M
- Employees
- 4
- Next earnings
- —
About Innovation Pharmaceuticals Inc.
Innovation Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to the development of small molecule therapies. Its pipeline targets a range of medical areas, including inflammatory diseases, cancer, dermatology, and infectious conditions. The company's lead drug candidate, Brilacidin, is currently in development for treating oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. Furthermore, Innovation Pharmaceuticals is advancing Kevetrin, an anti-cancer compound being investigated for ovarian cancer. The company holds a license agreement with Alfasigma S.p.A. and has a collaborative research agreement with Fox Chase Chemical Diversity Center, Inc. Established in 2005 and headquartered in Wakefield, Massachusetts, the firm operated as Cellceutix Corporation until its name change to Innovation Pharmaceuticals Inc. in June 2017.
- ISIN
- US45782D1000
- Founded
- 2005
- Listed since
- May 4, 2007
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €864.20 | -4.19% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $138.89 | -4.26% |
Figures last refreshed Aug 18, 2026.